								-0 41					001011							
FORM	4	UNIII	EDSI	AIE	S SE	:CU					NGE C	OMMI	SSION		OMB	APPRO	VAL			
Check this box if no longer subject to STATEME							IT OF CHANGES IN BENEFICIAL OWNERSHI									OMB Number: 3235-0287				
ions may contir		Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940																		
1. Name and Address of Reporting Person [*] Secora Michael						RECURSION PHARMACEUTICALS, (Check									k all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET					3. Date of Earliest Transaction (Month/Day/Year)											below)	specify			
					Line)															
(Street) SALT LAKE CITY UT 84101					Form fi									iled by More than One Reporting						
				_ R	ule '	10b	5-1(c)) Trar	nsac											
(City) (State) (Zip)						X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
	Tab	ole I - N			e Se	curit	ties Ac	quire	d, Di	sposed o	of, or Be	neficial	ly Owned							
1. Title of Security (Instr. 3)					/Year) Exe		ecution Date, iny						Securitie Benefici Owned	5. Amount of Securities Beneficially Owned Following		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership			
									v	Amount	(A) or (D)	Price	Transac	tion(s)			(Instr. 4)			
Class A Common Stock 12				/12/2023				M ⁽¹⁾		37,500	A	\$2.22	968,514		D					
Class A Common Stock 12/12/2					023			S ⁽¹⁾		25,000	D	\$7.3947	(2) 943	3,514	t D					
Class A Common Stock 12/13/2					023			M ⁽¹⁾		37,500	Α	\$2.22	98 1	1,014	4 D					
Class A Common Stock 12/13/20					23			S ⁽¹⁾		25,000	D	\$7.5908	(3) 956	5,014	D					
	-	Table II											Owned							
2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any		4. Transa	iction	5. Number ion of		6. Date Exerc Expiration Da		isable and	7. Title and Amount of Securities Underlying		8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficial Owned Following Reported	ily	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares								
\$2.22								(4)	,	03/03/2030	Class A Common Stock	0		685,17	7	D				
\$2.22	12/12/2023			M ⁽¹⁾			37,500	(5))	03/03/2030	Class A Common Stock	37,500	\$0.00	1,147,6	35	D				
\$2.22	12/13/2023			M ⁽¹⁾			37,500	(5))	03/03/2030	Class A Common Stock	37,500	\$0.00	1,110,1	35	D				
\$11.14								(6))	02/04/2032	Class A Common Stock	0		116,68	4	D				
\$11.14								02/04/2	2022	02/04/2032	Class A Common Stock	0		3,914		D				
\$8.55								(7)		02/01/2033	Class A Common Stock	0		404,85	7	D				
	FORM this box if no lc 16. Form 4 or ions may contin this box if no lc 16. Form 4 or ions may contin or start CURSION I O GRANDI AKE U (S Security (Inst Common Sta Common Sta Security Security Security	FORM 4 this box if no longer subject to 116. Form 4 or Form 5 ions may continue. See ion 1(b). The Address of Reporting Person Michael (First) CURSION PHARMACEUT O GRANDE STREET AKE UT (State) Tate Gammon Stock Common Stoc	FORM 4 UNITY this box if no longer subject to 116. Form 4 or Form 5 ions may continue. See tion 1(b). ST. d Address of Reporting Person* Michael (Middle) CURSION PHARMACEUTICALS OGRANDE STREET (Middle) CURSION PHARMACEUTICALS OGRANDE STREET 84101 (State) (Zip) AKE UT 84101 (State) (Zip) Table I - N Security (Instr. 3) Security (Instr. 3) Common Stock Common Stock Common Stock Conversion of Ecerois Perivative Security 3. Transaction Date Of Derivative Security 3A. Dee Execution (Month/Day/Year) \$2.22 12/12/2023 1 \$2.22 12/13/2023 1 \$11.14 1 1	NITED STATEMIN 106 Form 4 or Form 5 ions may continue. See itom (tb). STATEMIN 106 Form 4 or Form 5 ions may continue. See itom (tb). (First) (Middle) CURSION PHARMACEUTICALS O GRANDE STREET AKE UT 84101 (State) (Zip) Table 1 - NO-Deri Security (Instr. 3) Security (Instr. 3) 2. Transa Date (Month/DayYear) 2. Orgension price of Price of	FORM 4 UNITED STATES this box if no longer subject to 116. Form 4 or Form 5 bors may continue. See iton 1(b). STATEMENT Is Form 4 or Form 5 bors may continue. See iton 1(b). Filed pur row Michael	this box if no longer subject to 116. Form 4 or Form 5 ons may continue. See tion 1(b). STATEMENT OF ad Address of Reporting Person [®] Michael Illed pursuant 1 or Section 2. Insuent (First) (Middle) CURSION PHARMACEUTICALS O GRANDE STREET 2. Issuent 12/12/2 4. If Ame AKE UT 84101 (State) (Zip) Rule - (State) Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Common Execution Date, (Month/Day/Year) 4. Fransaction Common Stock 3. Transaction Date (Month/Day/Year) 3. Common Execution Date, (Month/Day/Year) 4. Fransaction Common Stock 3. Common Execution Date, Stock 4. Fransaction Common Stock 3. Common Execution Date, Stock 4. Fransaction Common Stock 3. Common Execution Date, Stock 4. Fransaction Common Stock 5. Fransaction Common Stock 5. Fransaction Common Stock <td< td=""><td>FORM 4 STATEMENT OF CALL TATEMENT OF CALL ISTATEMENT OF CALL Total colspan="2">Total colspan="2">Statement to the purplement of the purplem</td><td>FORM 4 UNITED STUDENT SUPPORT STATEMENT OF CHARMANCE UNITED STATES SUPPORT INTED STATES SUPPORT STATEMENT OF CHARMANCE UNITED STATES Michael Sister Name and Tic RECURSION PHARMACEUTICALS OGRANDE STREET Sister Name and Tic RECURSION PHARMACEUTICALS AKE UT Sister Name and Tic RECURSION PHARMACEUTICALS AKE UT Sister Name and Tic RECURSION PHARMACEUTICALS AKE UT Sister Name and Tic RECURSION PHARMACEUTICALS Constance Internet To Colspan="2">Contex Nite South in a Date of Earliest Transaction Date framework AKE UT Contex Nite South in a Date of Earliest Transaction Date framework Site I - Decrivative South in a Date of Earliest Transaction Date framework Common Stock 12/12/2023 Common Stock 12/12/2023 Site I - Decrivative South in a South Integration Date framework Site I - Decrivative South Integration Date framework Site I - Decrivative South Integration Date framework Si</td><td>INITED STATES SECURTISAN Washington, IC STATEMENT OF CHARGES IN STATEMENT OF CHARGES IN Submittion, Section 16(a) of the investion of address of Reporting Person' Michael Sister Name and Ticker of T Section 30(b) of the investion of address of Reporting Person' Michael (First) (Middle) (URSION PHARMACEUTICALS OGRANDE STREET Sister Name and Ticker of T Section 20(c) (State) (ZP) NAME (State) (ZP) Sister Name and Ticker of T Section 20(c) (State) (ZP) (State) (ZP) Sister Name and Ticker of T Section 20(c) (State) (ZP) Colspan="2">Sister Name and Ticker of T Section 20(c) (State) (ZP) Colspan="2">Sister Name and Ticker of T Section 20(c) (State) (ZP) Colspan="2">Colspan="2">Colspan="2">Sister Name and Ticker of T Section 20(c) (State) (ZP) Colspan="2">Colspan="2"Colspan="2">Colspan="2"Colspan="2"Colspan="2"Colspan="2"Colspan="2"Colspan="2"Colspa</td><td>INITED STATES SECURISE AND WARMED AND AND AND AND AND AND AND AND AND AN</td><td><text> TATATES SECURITES ADD EXCHA Wainington, D.c. 2008 STATEMENT CONSTRUCT SUBJECT S</text></td><td><text><table-container> INTRED SPACE S</table-container></text></td><td>ADDITICUATION CONTRIBUTION CONTRIBUTIO</td><td><section-header> BORM 3 DISTRUCTURE SUBJICATION SUB</section-header></td><td>NUMERONAL SUBJECT SUBJECT</td><td>NUNCED STATUS SECURICAL DE JUNICE DATAGES DE L'ANDER D</td><td>Image: Selection of the set of the</td></td<>	FORM 4 STATEMENT OF CALL TATEMENT OF CALL ISTATEMENT OF CALL Total colspan="2">Total colspan="2">Statement to the purplement of the purplem	FORM 4 UNITED STUDENT SUPPORT STATEMENT OF CHARMANCE UNITED STATES SUPPORT INTED STATES SUPPORT STATEMENT OF CHARMANCE UNITED STATES Michael Sister Name and Tic RECURSION PHARMACEUTICALS OGRANDE STREET Sister Name and Tic RECURSION PHARMACEUTICALS AKE UT Sister Name and Tic RECURSION PHARMACEUTICALS AKE UT Sister Name and Tic RECURSION PHARMACEUTICALS AKE UT Sister Name and Tic RECURSION PHARMACEUTICALS Constance Internet To Colspan="2">Contex Nite South in a Date of Earliest Transaction Date framework AKE UT Contex Nite South in a Date of Earliest Transaction Date framework Site I - Decrivative South in a Date of Earliest Transaction Date framework Common Stock 12/12/2023 Common Stock 12/12/2023 Site I - Decrivative South in a South Integration Date framework Site I - Decrivative South Integration Date framework Site I - Decrivative South Integration Date framework Si	INITED STATES SECURTISAN Washington, IC STATEMENT OF CHARGES IN STATEMENT OF CHARGES IN Submittion, Section 16(a) of the investion of address of Reporting Person' Michael Sister Name and Ticker of T Section 30(b) of the investion of address of Reporting Person' Michael (First) (Middle) (URSION PHARMACEUTICALS OGRANDE STREET Sister Name and Ticker of T Section 20(c) (State) (ZP) NAME (State) (ZP) Sister Name and Ticker of T Section 20(c) (State) (ZP) (State) (ZP) Sister Name and Ticker of T Section 20(c) (State) (ZP) Colspan="2">Sister Name and Ticker of T Section 20(c) (State) (ZP) Colspan="2">Sister Name and Ticker of T Section 20(c) (State) (ZP) Colspan="2">Colspan="2">Colspan="2">Sister Name and Ticker of T Section 20(c) (State) (ZP) Colspan="2">Colspan="2"Colspan="2">Colspan="2"Colspan="2"Colspan="2"Colspan="2"Colspan="2"Colspan="2"Colspa	INITED STATES SECURISE AND WARMED AND AND AND AND AND AND AND AND AND AN	<text> TATATES SECURITES ADD EXCHA Wainington, D.c. 2008 STATEMENT CONSTRUCT SUBJECT S</text>	<text><table-container> INTRED SPACE S</table-container></text>	ADDITICUATION CONTRIBUTION CONTRIBUTIO	<section-header> BORM 3 DISTRUCTURE SUBJICATION SUB</section-header>	NUMERONAL SUBJECT	NUNCED STATUS SECURICAL DE JUNICE DATAGES DE L'ANDER D	Image: Selection of the set of the			

Explanation of Responses:

1. Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023.

2. This transaction was executed in multiple trades at prices ranging from \$7.265 to \$7.53. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. This transaction was executed in multiple trades at prices ranging from \$7.34 to \$8.30 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. The option, originally for 1,125,000 shares, vests as to one forty-eighth (1/48th) of the shares subject to the award one month after March 1, 2020, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter.

5. The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events.

6. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. 7. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.

/s/ Jonathan Golightly,

attorney-in-fact

11/14/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.